Market Place
Sourcing Support
Medivir to present at the Pareto Securities Healthcare Conference
18 Sep 2024 //
PR NEWSWIRE
Medivir`s Fostrox + Lenvima Shows Promise In Liver Cancer
16 Sep 2024 //
PR NEWSWIRE
Medivir To Present Fostrox + Lenvima Data At ESMO And Host Webcast
12 Sep 2024 //
PR NEWSWIRE
MEDIVIR AB - INTERIM REPORT JANUARY - JUNE 2024
22 Aug 2024 //
PR NEWSWIRE
Medivir To Present Fostrox + Lenvima HCC Data At ESMO Conference
18 Jul 2024 //
PR NEWSWIRE
Number of shares and votes in Medivir AB on 28 June 2024
28 Jun 2024 //
PR NEWSWIRE
Fostrox + Lenvima® holds promise of greatly improved outcomes
27 Jun 2024 //
PR NEWSWIRE
Medivir Selects CRO For Phase 2b HCC Study With Fostrox + Lenvima
19 Jun 2024 //
PR NEWSWIRE
Medivir to present at Redeye Growth Day
30 May 2024 //
PR NEWSWIRE
Share Transactions Under LTIP 2024 At EssilorLuxottica
30 May 2024 //
PR NEWSWIRE
Medivir Tng348 Program Discontinued: By Licensee Tango Therapeutics
23 May 2024 //
PR NEWSWIRE
Resolutions at the Annual General Meeting in Medivir on 7 May 2024
07 May 2024 //
PR NEWSWIRE
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024
30 Apr 2024 //
PR NEWSWIRE
Medivir to Present Fostrox + Lenvima Data in HCC at ESMO GI
29 Apr 2024 //
PR NEWSWIRE
Medivir´s MIV-711 gets US FDA rare paediatric disease & orphan drug designation
26 Apr 2024 //
PHARMABIZ
FDA Grants Medivir`s MIV-711 RPD, ODD for Legg-Calvé-Perthes
25 Apr 2024 //
PR NEWSWIRE
Medivir Updates On FDA Meeting For Fostrox+Lenvima HCC Phase 2b
23 Apr 2024 //
PR NEWSWIRE
Medivir`s Vetbiolix: Positive VBX-1000 Proof-Of-Concept Results
15 Apr 2024 //
PR NEWSWIRE
Medivir to present at Investing in Oncology Forum on April 10
09 Apr 2024 //
PR NEWSWIRE
Medivir 2023 Annual Report published
04 Apr 2024 //
PR NEWSWIRE
Medivir to present at the Life Science Day in Gothenburg on March 6
04 Mar 2024 //
PR NEWSWIRE
Medivir announces the outcome of the directed share issue
26 Jan 2024 //
PR NEWSWIRE
Medivir to present at the Redeye Fight Cancer Day
24 Jan 2024 //
PR NEWSWIRE
Medivir invites to a conference call today on updated data at ASCO GI
23 Jan 2024 //
PR NEWSWIRE
Medivir carries out a directed share issue of approx. SEK 20 million
22 Jan 2024 //
PR NEWSWIRE
Fostrox + Lenvima shows improved rates to progression in advanced liver cancer
17 Jan 2024 //
PR NEWSWIRE
Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348
04 Jan 2024 //
PR NEWSWIRE
Medivir have agreed with Lonza to manufacture a fostrox GMP campaign
13 Dec 2023 //
PR NEWSWIRE
Medivir to present at the Carlsquare Equity Research Investor Day
06 Dec 2023 //
PR NEWSWIRE
Bulletin from Extraordinary General Meeting in Medivir AB (publ)
01 Dec 2023 //
PR NEWSWIRE
Quotient Sciences supports Medivir with updated formulation of fostrox
27 Nov 2023 //
PRESS RELEASE
Medivir announces updated formulation of fostrox
27 Nov 2023 //
PR NEWSWIRE
Medivir to present at the Redeye Life Science Day
22 Nov 2023 //
PR NEWSWIRE
Medivir to present at the Erik Penser Bank Company Event
21 Nov 2023 //
PR NEWSWIRE
Medivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC
13 Nov 2023 //
PR NEWSWIRE
Medivir to report new and updated data from ongoing phase 2a HCC study
25 Oct 2023 //
PR NEWSWIRE
Change in Medivir`s Board of Directors
20 Oct 2023 //
PR NEWSWIRE
Fostrox + Lenvima continues to show promising tumor control in HCC
05 Oct 2023 //
PR NEWSWIRE
Medivir to present at the Pareto Securities Healthcare Conference
14 Sep 2023 //
PR NEWSWIRE
Medivir presents data on additive activity of fostrox with Lenvima or sorafenib
07 Sep 2023 //
PR NEWSWIRE
Medivir reports promising interim data
04 Sep 2023 //
PR NEWSWIRE
Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape
01 Sep 2023 //
PR NEWSWIRE
Medivir to present at the Erik Penser Bank Company Event
23 Aug 2023 //
PR NEWSWIRE
Medivir partners with world-leading liver cancer experts in Advisory Council
07 Aug 2023 //
PR NEWSWIRE
China approves Medivir’s patent application for Fostrox
19 Jun 2023 //
PHARMACEUTICAL TECHNOLOGY
Medivir to present at the Redeye Growth Day
01 Jun 2023 //
PR NEWSWIRE
Medivir to present at the ABGSC Life Science Summit
30 May 2023 //
PR NEWSWIRE
Medivir Ab - Interim Report January - March 2023
27 Apr 2023 //
PR NEWSWIRE
Medivir presents new data at AACR showing significantly improved efficacy
17 Apr 2023 //
PR NEWSWIRE
Medivir 2022 Annual Report published
04 Apr 2023 //
PR NEWSWIRE
Notice of Annual General Meeting of Medivir AB (publ)
31 Mar 2023 //
PR NEWSWIRE
Medivir to present data on efficacy of fostrox in combination with anti-PD1
17 Mar 2023 //
PR NEWSWIRE
First patient dosed in Ph 2a part of Medivir`s study with fostrox with Lenvima
14 Mar 2023 //
PR NEWSWIRE
Medivir to present at the Stockholm Corporate Finance Life Science Day
08 Mar 2023 //
PR NEWSWIRE
Medivir to present at the Erik Penser Bank Healthcare Day
23 Feb 2023 //
PR NEWSWIRE
Medivir completes initial Phase Ib part of HCC therapy trial
20 Feb 2023 //
CLINICAL TRIALS ARENA
Medivir - Year-End Report January - December 2022
15 Feb 2023 //
PR NEWSWIRE
Medivir to present at the Redeye Fight Cancer Day
16 Jan 2023 //
PR NEWSWIRE
Medivir partner Infex Therapeutics receives FDA QIDP designation
11 Jan 2023 //
PR NEWSWIRE
